{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "carvedilol",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "( 2 ) Heart failure: Start at 10 mg once daily and increase to 20 mg, 40 mg, and then 80 mg once daily over intervals of at least 2 weeks.",
        "source": "US FDA label for carvedilol (Carvedilol Phosphate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/carvedilol.json",
        "verbatim": true
      },
      {
        "text": "( 2.1 ) Left ventricular dysfunction following myocardial infarction: Start at 20 mg once daily and increase to 40 mg then 80 mg once daily after intervals of 3 to 10 days.",
        "source": "US FDA label for carvedilol (Carvedilol Phosphate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/carvedilol.json",
        "verbatim": true
      },
      {
        "text": "( 2.2 ) Hypertension: Start at 20 mg once daily and increase if needed for blood pressure control to 40 mg then 80 mg once daily over intervals of 1 to 2 weeks.",
        "source": "US FDA label for carvedilol (Carvedilol Phosphate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/carvedilol.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Carvedilol phosphate extended-release capsules are intended for once-daily administration. Patients controlled with immediate-release carvedilol tablets alone or in combination with other medications may be switched to carvedilol phosphate extended-release capsules based on the total daily doses shown in Table 1. Table 1.",
        "source": "This line points to a numbered table that this card does not show - read that table in the label before you dose. US FDA label for carvedilol (Carvedilol Phosphate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/carvedilol.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "Patients at risk appear to be those with low blood pressure (systolic blood pressure less than 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal insufficiency.",
        "source": "US FDA label for carvedilol (Carvedilol Phosphate), section 'warnings and cautions', retrieved 2026-08-29",
        "cached_file": "labels/carvedilol.json",
        "verbatim": true
      }
    ],
    "hepatic": [
      {
        "text": "Concomitant administration with a diuretic can be expected to produce additive effects and exaggerate the orthostatic component of carvedilol action. 2.4 Hepatic Impairment Carvedilol phosphate extended-release capsules should not be given to patients with severe hepatic impairment [see Contraindications (4) ] .",
        "source": "US FDA label for carvedilol (Carvedilol Phosphate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/carvedilol.json",
        "verbatim": true
      }
    ],
    "pregnancy": [
      {
        "text": "Risk Summary Available data regarding use of carvedilol phosphate extended-release capsules in pregnant women are insufficient to determine whether there are drug-associated risks of adverse developmental outcomes.",
        "source": "US FDA label for carvedilol (Carvedilol Phosphate), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/carvedilol.json",
        "verbatim": true
      },
      {
        "text": "There are risks to the mother and fetus associated with poorly controlled hypertension in pregnancy.",
        "source": "US FDA label for carvedilol (Carvedilol Phosphate), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/carvedilol.json",
        "verbatim": true
      },
      {
        "text": "The use of beta blockers during the third trimester of pregnancy may increase the risk of hypotension, bradycardia, hypoglycemia, and respiratory depression in the neonate [see Clinical Considerations ] .",
        "source": "US FDA label for carvedilol (Carvedilol Phosphate), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/carvedilol.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "Risk Summary There are no data on the presence of carvedilol in human milk, the effects on the breastfed infant, or the effects on milk production.",
        "source": "US FDA label for carvedilol (Carvedilol Phosphate), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/carvedilol.json",
        "verbatim": true
      },
      {
        "text": "Carvedilol is present in the milk of lactating rats.",
        "source": "US FDA label for carvedilol (Carvedilol Phosphate), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/carvedilol.json",
        "verbatim": true
      },
      {
        "text": "The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for carvedilol phosphate extended-release capsules and any potential adverse effects on the breastfed infant from carvedilol phosphate extended-release capsules or from the underlying maternal condition.",
        "source": "US FDA label for carvedilol (Carvedilol Phosphate), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/carvedilol.json",
        "verbatim": true
      }
    ]
  }
}